Zymeworks Inc. Common Stock
$ 26.32
-3.77%
10 Apr - close price
- Market Cap 1,955,649,000 USD
- Current Price $ 26.32
- High / Low $ 27.29 / 25.85
- Stock P/E N/A
- Book Value 3.60
- EPS -1.08
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -0.27 %
- 52 Week High 28.49
- 52 Week Low 10.69
About
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in Vancouver, Canada.
Analyst Target Price
$40.08
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-02 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-03-04 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-03-06 | 2023-11-07 | 2023-08-10 | 2023-05-08 |
| Reported EPS | -0.55 | -0.26 | 0.03 | -0.3 | -0.31 | -0.39 | -0.49 | -0.42 | -0.2 | -0.41 | -0.76 | -0.36 |
| Estimated EPS | -0.3224 | -0.46 | -0.46 | -0.73 | -0.0922 | -0.41 | -0.31 | -0.29 | -0.43 | -0.47 | -0.47 | -0.54 |
| Surprise | -0.2276 | 0.2 | 0.49 | 0.43 | -0.2178 | 0.02 | -0.18 | -0.13 | 0.23 | 0.06 | -0.29 | 0.18 |
| Surprise Percentage | -70.5955% | 43.4783% | 106.5217% | 58.9041% | -236.2256% | 4.878% | -58.0645% | -44.8276% | 53.4884% | 12.766% | -61.7021% | 33.3333% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.1 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZYME
2026-03-06 20:10:42
Zymeworks Inc. reported its financial results for the fourth quarter and full year 2025, highlighting a strategic shift towards predictable revenue streams and disciplined capital allocation. The company announced significant progress with its partnered programs, including regulatory submissions and approvals for Ziihera, and reported a substantial increase in total revenue for 2025 alongside a reduced net loss, supported by a $250.0 million non-recourse royalty-backed note financing. Zymeworks also provided an update on its share repurchase program and financial outlook, projecting its existing cash alongside anticipated milestones and financing to fund operations beyond 2028.
2026-03-06 16:39:06
Zymeworks reported a significant financial improvement in 2025, with total revenue rising 39% to $106.0 million and its net loss narrowing by 34% to $81.1 million. The company ended the year with strong liquidity, holding $270.6 million in cash and short-term investments, further bolstered by a new $250.0 million royalty-backed note from Royalty Pharma. This strategic financing and disciplined expense management are expected to extend Zymeworks' cash runway beyond 2028, supporting ongoing share repurchases and potential acquisitions.
2026-03-03 12:53:12
Zymeworks Inc. discussed its Q4 2025 earnings and provided updates on its clinical programs and strategic financing. Key highlights include positive Phase III results for zanidatumab in HER2-positive GEA, a new $250 million royalty-backed note financing with Royalty Pharma to fund share repurchases and potential acquisitions, and progress in other clinical trials such as ZW251 and ZW191. The company reiterated its commitment to disciplined capital allocation and expansion of its royalty-generating asset portfolio.
2026-03-03 07:10:25
Zymeworks announced its fourth-quarter and full-year 2025 financial results, highlighting a 39% increase in total revenue to $106.0 million and a 34% reduction in net loss to $81.1 million compared to 2024. The company also provided a corporate update, including a $250.0 million royalty-backed note financing with Royalty Pharma, $62.5 million utilized for share repurchases, and significant progress with its partnered programs Ziihera and pasritamig, anticipating regulatory approvals and milestone payments. Zymeworks reported $270.6 million in cash, cash equivalents, and marketable securities as of December 31, 2025, projecting a cash runway beyond 2028.
2026-03-02 11:29:20
Zymeworks Inc. has secured a $250 million non-recourse royalty-backed note financing agreement with Royalty Pharma. This deal leverages 30% of future Ziihera (zanidatamab-hrii) royalties from Jazz Pharmaceuticals and BeOne Medicines as collateral, providing Zymeworks with non-dilutive capital. The funding aims to strengthen Zymeworks' balance sheet, support its stock repurchase program, facilitate potential strategic acquisitions, and extend its cash runway beyond 2028.
2025-12-11 23:09:45
Zymeworks Inc. has achieved a significant breakthrough with its lead cancer drug, Zanidatamab, proving effective in Phase 3 trials, potentially generating billions in sales. This success is poised to invigorate Vancouver's biotech sector by creating jobs, attracting investment, and fostering a skilled workforce. The company also has other promising drugs in its pipeline and plans to diversify by investing in future royalty streams from other biotech firms.
